Sugi Predict

Sugi Predict / Compounds / SCHEMBL20449461

SCHEMBL20449461

SCHEMBL20449461

COc1ccc(CN(c2ncns2)S(=O)(=O)c2cc(F)c(Br)cc2F)c(OC)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 4/20 0.40
▸ HDAC8 Q9BY41 1/20 0.35
▸ POLB P06746 2/20 0.35
▸ TP53 P04637 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ KEAP1 Q14145 1/20 0.33
▸ NFE2L2 Q16236 1/20 0.33
▸ BMP1 P13497 1/20 0.33
▸ RORC P51449 1/20 0.32
▸ CA2 P00918 1/20 0.32
▸ HTR2A P28223 1/20 0.32
▸ HTR2C P28335 1/20 0.32
▸ LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29835279 1.00 SCN9A (0.40) SCN9AHDAC8POLBTP53GAA
SCHEMBL18983147 0.96 SCN9A (0.40) SCN9AHDAC8POLBTP53GAA
SCHEMBL22089152 0.94 SCN9A (0.40) SCN9AHDAC8POLBTP53GAA
SCHEMBL29835251 0.92 SCN9A (0.42) SCN9AHDAC8POLBTP53GAA
SCHEMBL1094096 0.92 SCN9A (0.42) SCN9AHDAC8POLBTP53GAA
SCHEMBL28912753 0.92 SCN9A (0.39) SCN9AHDAC8POLBTP53GAA
SCHEMBL22034926 0.92 SCN9A (0.39) SCN9AHDAC8POLBTP53GAA
SCHEMBL21865565 0.89 SCN9A (0.40) SCN9AHDAC8POLBTP53GAA
SCHEMBL20115730 0.89 SCN9A (0.40) SCN9AHDAC8POLBTP53GAA
SCHEMBL30479338 0.89 SCN9A (0.40) SCN9AHDAC8POLBTP53GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171516-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-06-10 — — US disclosed
US-10787446-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2020-09-29 — — US disclosed
WO-2020052509-A1 SULFONAMIDE COMPOUND SERVING AS SODIUM CHANNEL BLOCKER AND USES THEREOF 成都康弘药业集团股份有限公司 2020-03-19 — — WO disclosed
US-20180291014-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-10-11 — — US disclosed
EP-3356360-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF Genentech, Inc. (US) 2018-08-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180291014-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF AVPR1B, C3AR1, RHEB SCN9A 256/4885HDAC8 1391/4885POLB 1127/4885
US-10787446-B2 Therapeutic compounds and methods of use thereof AVPR1B, C3AR1, RHEB SCN9A 256/4885HDAC8 1391/4885POLB 1127/4885
US-20210171516-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF AVPR1B, C3AR1, RHEB SCN9A 256/4885HDAC8 1391/4885POLB 1127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.